PensionDanmark Pensionsforsikringsaktieselskab Increases Stake in Amgen Inc. $AMGN

PensionDanmark Pensionsforsikringsaktieselskab lifted its position in Amgen Inc. (NASDAQ:AMGN) by 12.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 108,300 shares of the medical research company’s stock after acquiring an additional 11,821 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Amgen were worth $39,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. 55 North Private Wealth LLC raised its position in shares of Amgen by 5.5% in the second quarter. 55 North Private Wealth LLC now owns 957 shares of the medical research company’s stock worth $347,000 after acquiring an additional 50 shares during the period. Emprise Bank acquired a new stake in shares of Amgen during the 2nd quarter valued at about $204,000. Evanson Financial LLC purchased a new position in shares of Amgen in the 2nd quarter valued at about $563,000. Foster Group Inc. increased its stake in shares of Amgen by 3.9% in the 2nd quarter. Foster Group Inc. now owns 2,616 shares of the medical research company’s stock valued at $947,000 after purchasing an additional 99 shares in the last quarter. Finally, JGP Wealth Management LLC raised its holdings in Amgen by 2.3% in the 2nd quarter. JGP Wealth Management LLC now owns 43,268 shares of the medical research company’s stock worth $15,668,000 after purchasing an additional 975 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7%

AMGN stock opened at $404.85 on Friday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $418.40. The business’s 50-day moving average is $361.29 and its 200 day moving average is $355.86. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44. The stock has a market cap of $218.50 billion, a price-to-earnings ratio of 25.16, a PEG ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.47 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is currently 70.15%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
• Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
• Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMGN. Sanford C. Bernstein raised their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday. Daiwa Securities Group reduced their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Bank of America lifted their price target on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday. Finally, Mizuho boosted their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $367.93.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.